High time to innovate in Pharma sector to do business differently

“Its a high time that has come for pharma firms to innovate and do business differently”, says Dr Dinesh Dua, CEO and Whole-time Director, Nectar Lifesciences Ltd and chairman, Pharmexcil, in an interaction with Vijay C Roy on challenges confronting the industry. Excerpts.

In an interaction, it was discussed that:-

We faced various types of issues when the lockdown was imposed, in terms of transportation and manpower. Though pharma sector had been classified as essential services and were allowed to operate, there was huge compression on both inter-state transportation and movement of manpower.
Before the lockdown, capacity utilisation was around 80% across the country. It crashed to 20-25% in the first fortnight after the lockdown was imposed. Things started improving and production rose to 40% but that is in Telangana and Andhra Pradesh. In North India, especially in the Baddi belt, it is not more than 30%.

Domestic supply is still operating at 25-30%, but the exports got a massive hit as the JNPT in Mumbai was shut down and there were no flights. On an all-India basis, we were looking at exports worth $22 billion, but due to the lockdown in March only, we missed the target by $1 billion in just five days.

Since the pharmaceutical industry is dominated by the MSMEs, which contribute 75%. They are in desperate need of funds and so are the big companies. As their receivables are not coming, the entire cash flow is stuck. First and foremost, the government needs to give some kind of package in the form of salary and wages support. If nothing is done in a week or so, 50% units won’t be able to survive.

Initially, the traders made a killing. Later, the prices came down by 50% as compared to what was quoted in the first 15 days of the lockdown. Meanwhile, some consignments started arriving from China, particularly at Delhi Dry Port. JNPT has started functioning around a week ago. We do have 25-30% supply now, but that’s not enough. We have around 20,000 formulators but only 4,000-5,000 are being served.

Conclusion:

Wheat must be separated from chaff, the employees who have reported for work and those who haven’t. Technology is going to become an enabler. Video-conferencing and webinars are the order of the day. And now is the time to innovate and do business differently.

  • Related Posts

    • Pharma
    • April 15, 2024
    • 37 views
    Glenmark recalls 6,528 bottles of BP drug in US

    Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydrochloride extended-release capsules, a medication used to treat high blood pressure in the American market due to failed dissolution specifications, informed USFDA…

    • Pharma
    • April 15, 2024
    • 28 views
    Pharma Exports To US Surges 15% In 11 Months Of FY24

    Mumbai: After a lull, India’s pharma exports to the US have surged 15% in the first 11 months of the last financial year despite regulatory challenges and rising pricing pressures. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Glenmark recalls 6,528 bottles of BP drug in US

    Glenmark recalls 6,528 bottles of BP drug in US

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    Pharma Exports To US Surges 15% In 11 Months Of FY24

    CAHO Naa Patients Se Pyaar Hai

    CAHO Naa Patients Se Pyaar Hai

    ‘Ram Kit’, Available At Many Drugstores In Agra

    ‘Ram Kit’, Available At Many Drugstores In Agra

    Uttarakhand SLA, Ayush Ministry Stalled Action Against Patanjali: RTI Activist

    Uttarakhand SLA, Ayush Ministry Stalled Action Against Patanjali: RTI Activist

    CDSCO Releases Draft GDP Guidelines For Pharmaceutical Products

    CDSCO Releases Draft GDP Guidelines For Pharmaceutical Products